Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640315 | 0.87 | MAPT (0.36) | MAPTKDM4E | |
| SCHEMBL30669244 | 0.87 | MAPT (0.36) | MAPTKDM4E | |
| SCHEMBL4537605 | 0.82 | GRIN2D (0.42) | — | |
| SCHEMBL19759439 | 0.76 | SMN1; SMN2 (0.35) | MAPTKDM4E | |
| SCHEMBL6664133 | 0.71 | HTT (0.41) | MAPTKDM4EGAA | |
| SCHEMBL4541092 | 0.69 | OPRK1 (0.39) | MAPTHPGD | |
| SCHEMBL21326695 | 0.69 | HSP90AB1 (0.38) | DGAT2MAPTKDM4EALDH1A1GAA | |
| SCHEMBL23363895 | 0.69 | CCNT1 (0.35) | MAPTKDM4E | |
| SCHEMBL6664140 | 0.68 | KMT2A (0.35) | KDM4EGAA | |
| SCHEMBL8614375 | 0.67 | GRM1 (0.33) | PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283264-A1 | Oxazolidinones as Modulators of MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-08 | — | — | US | disclosed |
| WO-2012064603-A1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283264-A1 | Oxazolidinones as Modulators of MGLUR5 | GRM5, GRIK5, GRM1 | PPARD 432/4885DGAT2 1915/4885MAPT 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.